Elezanumab (Anti-RGMA)
Elezanumab (Anti-RGMA) (A2370-GRP)
Products
Description
Elezanumab (Anti-RGMA) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway with IC50 of 97 pM. MW: 146.44 kD.
Specifications
| Manufacturer | Selleck Chemicals LLC |
|---|---|
| Manufacturer Cat# | A2370 |
| Target | TGF-beta/Smad |